Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer − PORTEC-4a an international, randomised, phase 3 trial

20260 citationsJournal Articlehybrid Open Access

Authors

Anne Sophie V M van den Heerik · Leiden University Medical Center

Nanda Horeweg · Leiden University Medical Center

Marie A.D. Haverkort · Radiotherapiegroep

Nienke Kuijsters · Maastro Clinic

Stefan Kommoss · University Children's Hospital Tübingen

Friederike Koppe · Instituut Verbeeten

Marlies E Nowee

Abstract

Individualised adjuvant treatment based on a molecular-integrated-profile was more cost-effective than standard VBT for patients with HIR-EC. These results further support the implementation of the molecular-integrated-profile in routine clinical practice.

Topics & Keywords

Endometrial and Cervical Cancer Treatments PARP inhibition in cancer therapy Statistical Methods in Clinical Trials

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: Radiotherapy and Oncology

Volume 217, pp. 111406-111406

DOI: 10.1016/j.radonc.2026.111406

Field-Weighted Citation Impact: 0.00